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Background. Increasing antibiotic resistance warrants therapeutic alternatives. Here we investigated the efficacy of bacterio-
phage-therapy (phage) alone or combined with antibiotics against experimental endocarditis (EE) due to Pseudomonas aeruginosa, 
an archetype of difficult-to-treat infection.
Methods. In vitro fibrin clots and rats with aortic EE were treated with an antipseudomonas phage cocktail alone or combined 
with ciprofloxacin. Phage pharmacology, therapeutic efficacy, and resistance were determined.
Results. In vitro, single-dose phage therapy killed 7 log colony-forming units (CFUs)/g of fibrin clots in 6 hours. Phage-resistant 
mutants regrew after 24 hours but were prevented by combination with ciprofloxacin (2.5 × minimum inhibitory concentration). 
In vivo, single-dose phage therapy killed 2.5 log CFUs/g of vegetations in 6 hours (P < .001 vs untreated controls) and was compa-
rable with ciprofloxacin monotherapy. Moreover, phage/ciprofloxacin combinations were highly synergistic, killing >6 log CFUs/g 
of vegetations in 6 hours and successfully treating 64% (n = 7/11) of rats. Phage-resistant mutants emerged in vitro but not in vivo, 
most likely because resistant mutations affected bacterial surface determinants important for infectivity (eg, the pilT and galU genes 
involved in pilus motility and LPS formation).
Conclusions. Single-dose phage therapy was active against P. aeruginosa EE and highly synergistic with ciprofloxacin. Phage-
resistant mutants had impaired infectivity. Phage-therapy alone or combined with antibiotics merits further clinical consideration.
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The global increase in antibiotic resistance is reviving the need for 
alternative antimicrobial strategies, including phage therapy. This 
“forgotten cure” was developed in parallel to antibiotics during 
the first half of the 20th century and is still commonly used in 
countries of the former Soviet Union [1]. However, it was not 
developed on a large scale in Western countries, and informa-
tion on phage pharmacokinetics/pharmacodynamics (PK/PD), 
drug interactions, in vivo efficacy, and emergence of resistance 
remains scarce. Phages have been administered by various routes, 
including inhalation for pneumonia (reviewed in [2]), surgical 
rinsing for chronic osteomyelitis [3], and intravenous injection 
for severe systemic infections, such as typhoid fever (reviewed in 
[4]). However, only a few studies provide a comprehensive pic-
ture linking phage pharmacology to antibacterial efficacy [5, 6]. 
Moreover, with few exceptions [6], the emergence of phage resis-
tance is seldom addressed, even in recent clinical studies [7–9].
Detailed understanding of bacterial resistance to phages is 
critical if phages were to be used more broadly in the clin-
ical setting. Phage-resistant bacteria can result from several 
mechanisms, including modification of cell-surface receptors, 
restriction-modification of incoming (foreign) phage DNA, 
or interphage immunity [10]. Resistance mutations may arise 
spontaneously in vitro and are likely to be selected in vivo as 
well [6]. Some mutations may affect LPS (a common phage 
receptor) and impact bacterial fitness or virulence [11–13]. 
However, other kinds of mutations or further mutations restor-
ing virulence cannot be excluded and must be scrutinized.
The intrinsic bactericidal properties of anti-infective com-
pounds are most reliably studied in models of therapeutic 
sanctuaries, where natural host defenses are poorly involved. 
Experimental endocarditis (EE) and experimental meningitis 
are 2 such models. Experimental meningitis implicates a spe-
cial anatomical setting where drug distribution depends on the 
blood–brain barrier. In contrast, EE mirrors the general situ-
ation encountered in many deep-seated infections. Moreover, 
endocarditis pathogens surround themselves with amorphous 
aggregates of platelet-fibrin clots, which cellular host defenses 
cannot penetrate (for review see [14]). Thus, the capability of 
antimicrobials to penetrate into vegetations is a critical issue.
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In these experiments, we systematically explored the efficacy 
of a clinically used antipseudomonas phage cocktail (cocktail 
PP1131 currently investigated in the multicentric Phagoburn 
clinical trial for treatment of burn-wound infections; http://
www.phagoburn.eu) in a dual in vitro and in vivo model of 
experimental endocarditis due to Pseudomonas aeruginosa.
Phage therapy alone was active both in vitro and in animals 
with EE. Moreover, it was highly synergistic with antibiotics. 
Although phage-resistant bacteria emerged in vitro, they were 
not detectable in vivo due to fitness alteration in the animal 
milieu. These results suggest that phage therapy alone or com-
bined with antibiotics (in this case ciprofloxacin) deserves fur-
ther consideration for future clinical application.
METHODS
Strains, Phage Cocktail, and Antibiotics
A total of 33 P. aeruginosa reference strains and clinical isolates 
from our own clinical strain collection were used in in vitro 
susceptibility determinations (Supplementary Table  1). These 
isolates were not meant to cover the diversity of contemporary 
pseudomonas from our hospitals but rather to select strains 
with extreme phenotypes to be tested in our experiments. 
Growth conditions and reagents are given in the Supplementary 
Materials.
In Vitro Studies
The host range of the individual phages composing the PP1131 
cocktail was determined using spot or plaque assays [15]. 
Experiments were done in triplicates. Plasma clots were pre-
pared in 96-well microplates, as previously described [16]. 
Phage titers were measured by plaque assays [15]. The activity 
of the phage cocktail was considered bactericidal when it killed 
≥3 log colony-forming units (CFUs) of the starting inoculum in 
the clot. Details are provided in the Supplementary Materials.
Animal Studies
Experiments were approved by and in adherence with the 
guidelines of the Swiss Animal Protection Law, Veterinary 
office, State of Vaud. Experiments were performed under 
license number 879.9 and in accordance with the regulations 
of the cantonal committee on animal experimentation of the 
State of Vaud, Switzerland. The production of catheter-induced 
aortic vegetations and the installation of an intravenous line 
into the superior vena cava, connected to an infusion pump 
to deliver the phage cocktail, were performed in female Wistar 
rats as previously described [17]. Details are provided in the 
Supplementary Materials.
Histology
Semithin and ultrathin sections were prepared as previously 
described [18] and cut with a Leica Ultracut microtome. Sections 
were stained for light microscopy using the modified Brown 
and Brenn method, as previously described [19]. Ultrathin sec-
tions of 50 nm were stained as previously described [18]. For 
phage observation, phage cocktail was adsorbed on copper 200-
mesh grid coated with Formvar-carbon and stained with uranyl 
acetate. Micrographs were taken with a transmission electron 
microscope FEI CM100 at an acceleration voltage of 80 kV with 
a TVIPS TemCam-F416 digital camera (EMF, UNIL).
Cytokine Measurements
The serum inflammatory cytokines interleukin 1β (IL-1β), 
interleukin 6 (IL-6), and tumor necrosis factor α (TNFα) were 
quantified prior to infection (24 hours after surgery), prior to 
therapy (18 hours after bacterial inoculation), and at sacrifice 
(6 hours after onset of therapy). Plasma was kept at −80°C, and 
cytokines titers were measured using the Biorad Bio-Plex Rat 
Cytokine Kit in a Luminex 200 system and following manufac-
turer’s recommendations (MEF platform, UNIL).
Detection and Characterization of Phage Resistance
Phage-resistant bacteria were isolated from broth cultures, in 
vitro fibrin clots, and rat vegetations by plating on blood agar 
plates containing 1010 PFU (plaque forming unit) preabsorbed 
phages. Resistance rates were determined as the number of 
bacteria growing on plates preadsorbed with phages divided by 
the number of bacteria growing on plain plates. In vivo infec-
tivity of phage resistance was assessed by inoculating rats with 
catheter-induced aortic vegetations as previously described. 
Full genomic DNA sequencing was performed by the Center 
for Integrative Genomics (University of Lausanne, Switzerland) 
using the Pacific Biosciences RSII platform. Total DNA was 
extracted using the DNeasy Blood and Tissue kit according to 
manufacturer’s instructions. GenDB [20], BLASTn [21], and 
BRIG [22] were used for genomic analysis. Subsurface twitch-
ing motility tests were performed as described [23]. LPS was 
extracted using the iNTRON LPS extraction kit, resolved on 
NuPAGE 4%–12% BisTris gels, and silver stained as previously 
described [24]. Details are provided in the Supplementary 
Materials.
RESULTS
Pseudomonas aeruginosa Host Range of Individual Phages of the PP1131 
Cocktail
The 12 phages contained in the PP1131 cocktail were evalu-
ated for their ability to lyse a panel of 33 laboratory and clini-
cal isolates of P. aeruginosa from our own collection using spot 
assays (Supplementary Tables 1 and 2). This test showed that 31 
of 33 (94%) of the P. aeruginosa isolates were lysed by at least 
2 phages, whereas only strains PA7 and PA10 were resistant 
to the 12 phages. The relatedness of the 12 phages regarding 
strain specificity was further evaluated by hierarchical cluster 
analysis based on a binary matrix derived from the spot assay. 
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Supplementary Figure 1 indicates that the phages of the cocktail 
were different from each other regarding their host specificity 
profiles, thus ensuring coverage of multiple strains.
Of note, spot assays indicate both lysis from within (due to 
productive phage infection) and lysis from without (due to 
phage attachment only). Therefore, although they assess spec-
ificity of phage–bacteria interactions, they may underestimate 
genuine productive infectivity. In the present experiments, the 
PP1331 phage cocktail achieved productive infection in 28 of 33 
(84%) of the tested strains (Supplementary Figure 2).
Activity of the Phage Cocktail in the In Vitro Fibrin-Clot Model
The efficacy of the cocktail was tested in fibrin clots simulat-
ing endocarditis vegetations [16]. Two P.  aeruginosa strains 
were used: namely, strain P7, which was not infected by any of 
the cocktail’s phages, and strain CHA which was susceptible to 
all of them. For resistant strain PA7, no phage-induced killing 
and no in situ phage amplification were observed (Figure 1A). 
Moreover, physical disintegration of the clots, possibly due to 
the action of bacterial proteases, was observed after 24 hours 
(Figure 1C).
In contrast, a significant loss of bacterial viability of approx-
imately 6 log CFUs/g was observed after 6 hours when CHA-
infected clots were challenged with the cocktail (Figure  1I 
(P  =  .0001 compared with the initial bacterial load). Phage-
induced killing was accompanied by a phage amplification of 
5 log PFUs/g of clots (P  =  .0001 compared with noninfected 
clots). In addition, phage-induced bacterial killing prevented 
bacterial-induced clot disintegration (Figure  1D), indicating 
that phages diffused through the fibrin meshwork and killed 
bacteria located inside the clots. Yet, the sharp initial phage-in-
duced killing was followed by bacterial regrowth after 24 hours 
(Figure 1B). This regrowth was caused by the development of 
phage-resistant bacterial mutants and was not accompanied by 
further phage amplification.
Frequency of Phage Resistance in Broth Cultures and Fibrin Clots
In the absence of phages, spontaneous resistant mutants 
occurred at an average frequency of ca 10–7 and at ca 10–8 against 
the whole cocktail (result not shown), both in batch cultures 
and in fibrin clots after 6 hours and 24 hours (Supplementary 
Table  3, column 2). In contrast, the proportion of phage-re-
sistant bacteria increased sharply after exposure to phages 
due to the replacement of phage-susceptible bacteria by resis-
tant subpopulations, (ie, 10–4 at 6 hours and 10–2 at 24 hours) 
(Supplementary Table 3, columns 5 and 6).
Prevention of Phage Resistance Using Phage/Antibiotic Combinations
To prevent the development of phage-resistant subpopulations, 
we attempted to combine phages with antibiotics. Combining 
the phage cocktail with 2.5 times the minimum inhibitory con-
centration (MIC) of ciprofloxacin or meropenem inhibited the 
Figure 1. Activity of phage cocktail PP1131 in in vitro fibrin clots. Clots were produced from rat plasma and infected with 108 colony-forming units (CFUs)/mL of either 
phage-resistant Pseudomonas aeruginosa strain PA7 (A) or phage-susceptible strain CHA (B). Clots were left untreated (solid lines) or exposed to 108 PFUs/mL of PP1131 for 
24 hours at 37°C (dashed lines). Phage titers in noninfected clots (solid lines) and in PA7-infected or CHA-infected clots (dashed lines) were determined 6 hours and 24 hours 
after exposure to the phage cocktail. Clots infected with strain PA7 lysed in spite of phage treatment (C), whereas those infected with phage-susceptible CHA and treated 
with phages remained intact (D). P values were determined using the Mann-Whitney test.
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regrowth of phage-resistant mutants after 24 hours (Figure 2A 
and 2B, dashed dotted lines, respectively). Moreover, the 2 
antibiotics were highly synergistic with phages at 24 hours, as 
defined by a ≥3 log CFUs/mL decrease in bacterial viable counts 
when compared with single phage or antibiotic therapy alone.
Phage Pharmacokinetics
The pharmacokinetics of the phage cocktail were assessed in 
the plasma and tissues of noninfected rats with catheter-in-
duced aortic vegetations following a single intravenous bolus 
injection or during continuous infusion (Figure 3A, solid and 
dashed line, respectively). A  high plasma titer (8.5  ±  1.5 log 
PFUs/mL) was measured 1 hour after bolus injection, followed 
by a continuous decrease to 4.9 ± 0.6 log PFUs/mL at 24 hours 
(elimination half-life = ca 2.3 hours). In parallel, the concen-
trations of phages in vegetations decreased from 7.5  ±  0.3 to 
6.2 ± 0.9 log PFUs/g between 6 hours and 24 hours after admin-
istration. A similar tendency was observed in the spleen, kid-
ney, liver, lung, and brain (elimination half-life = ca 9 hours) 
(Supplementary Figure 3). This demonstrated phage diffusion 
into the organs and delayed phage clearance compared with 
plasma. During continuous infusion, phage titers in plasma 
progressively increased to reach a plateau of 8.5 ± 0.2 log PFUs/
mL after 6 hours, which is comparable with to the concentration 
achieved after 1 hour following bolus injection. Phage concen-
trations in the vegetations and organs remained high after 24 
hours (7.4 ± 0.9 log PFUs/mL) (Supplementary Figure 3).
Treatment of Experimental Endocarditis
Inoculation with 108 CFUs of P.  aeruginosa CHA induced 
EE with bacterial loads in vegetations of control rats of >8 
log CFUs/g 18 hours after bacterial challenge (Figure  3B). 
Administration of the phage cocktail 18 hours after bacterial 
challenge by either continuous or bolus injection decreased 
median vegetation bacterial titers by 3.0 and 2.3 log CFUs/g, 
respectively, within 6 hours of therapy (Figure 3B) (P < .0001 
compared with treatment onset). No significant difference 
between the 2 routes of administration was observed. Notably, 
a single bolus injection of ciprofloxacin simulating a single oral 
dose of 750 mg in adults [17] decreased median vegetation bac-
terial titers by 2.6 log CFUs/g (Figure 3B), which was compara-
ble with phage therapy. Moreover, the combination of phages 
with ciprofloxacin was highly synergistic, resulting in negative 
vegetation cultures in 7 of 11 rats receiving combined therapy 
after 6 hours, as compared with 0 of 28 in phage-alone or cipro-
floxacin-alone treated groups (Figure 3B) (P < .005). Likewise, 
the residual median vegetation bacterial titers of ≤2 log CFUs/g 
in the combined therapy group were significantly lower than 
the ≥6 log CFUs/g titers detected in the monotherapy groups 
(P < .0001).
In Situ Penetration of Phages in Valve Tissues
Optical microscopy and transmission electron microscopy 
were performed on vegetation samples to visualize the presence 
and activity of phages inside the vegetations. Figure 4 presents 
relevant pictures of these experiments, including intravegeta-
tion P. aeruginosa in untreated rats (Figure 4A and 4B), nega-
tively stained phages from the cocktail with a capsid size of ca 
70 nm (Figure 4C), and intravegetation lysed bacteria in phage-
treated rats with bacterial ghosts containing phage particles 
(Figure 4D).
Correlation Between Phage Multiplication, Antimicrobial Activity, and 
Cytokine Production
In vivo antibacterial activity correlated with phage amplifica-
tion (ca 3 log PFUs/g of vegetations) after both continuous and 
Figure 2. Bactericidal synergism between phages and selected antibiotics. Bacterial killing by phage-antibiotic combinations was tested by using 108 PFUs/mL of PP1131 
with 2.5-times the minimum inhibitory concentration (MIC) of ciprofloxacin (A) or meropenem (B) (MIC of 0.19 µg/mL and 0.125 µg/mL, respectively). Each value represents 
the mean ± SD of 4–16 independent clots. Abbreviation: ABT, antibiotic.
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bolus injection (Figure  3C). This relation was further under-
lined by the scatter plot presented in Figure 3D, which showed 
a significant inverse correlation between phage and bacterial 
concentrations in the vegetations (correlation value r = −0.66, 
Pearson 2-tailed correlation test; P = .003).
Successful phage therapy also correlated with the pro-
duction of specific inflammatory cytokines (Figure  5). 
Concentrations of IL-1β, IL-6, and TNFα in plasma were 
quantified by Luminex first before inoculation, second before 
treatment onset, and lastly after 6 hours of phage therapy in 
uninfected and infected rats (Figure 5A). Several observations 
were drawn from these measurements. First, although there 
were trends in cytokine-induction by bacteria and phages 
alone, these were not statistically significant. Second, TNFα 
levels remained essentially unaltered in all of the groups 
throughout the experiment. Finally, only phage treatment, 
but not ciprofloxacin, significantly increased plasma levels of 
IL-1β and IL-6 (Figure 5B). Because ciprofloxacin is not bacte-
riolytic, the increase in IL-1β and IL-6 levels was likely related 
to phage-induced bacterial lysis.
Phage Resistance in Experimental Endocarditis 
Because spontaneous phage-resistant mutants occurred at a 
rate of 10–7 in batch cultures and fibrin clots, they were also 
expected to emerge in infected vegetations. To test this assump-
tion, phage-resistant mutants were sought in infected valves by 
plating vegetation extracts directly on agar plates containing 
preadsorbed phages. Unexpectedly, no phage-resistant mutants 
could be isolated from the infected vegetations either before or 
after therapy, therefore suggesting that phage resistance might 
result in altered virulence or fitness and interfere with success-
ful bacterial survival or growth in vivo. Two resistant isolates 
recovered from fibrin clots, 19/2 and 24/2, which showed dif-
ferent phage resistance patterns, were further characterized to 
Figure 3. Pharmacokinetics/pharmacodynamics (PK/PD) and therapeutic efficacy of phage cocktail PP1131 and ciprofloxacin in rats with experimental endocarditis (EE) due 
to Pseudomonas aeruginosa CHA. A, Pharmacokinetics in the absence of infection of phage cocktail PP1131 in rat plasma after either a single intravenous bolus injection 
(1 mL of 1010 PFUs/mL in 1 minute, dashed line, Bolus) or the same amount of phages administered through continuous infusion (0.1 mL/h of 1010 PFUs/mL over 24 hours, solid 
line: continuous infusion). Each value represents the mean ± SD from 8–10 individual animals. B, Bacterial loads of infected vegetations after 6 hours of phage treatment 
administered through continuous infusion or in single bolus and treatment with ciprofloxacin alone or combined with phages. Each dot represents the vegetation of a single 
animal. The mode of injection and type of treatment are indicated at the top of columns (C.I.: continuous infusion; φ: phages). Statistical results are indicated at the bottom 
of columns (†: control vs all types of treatment, P < .0005; ‡: combination vs control and all other types of treatments, P < .0001; results were compared by the Mann-Whitney 
test). C, Phage titers in vegetations measured in uninfected rats treated with bolus phage injection (control) or infected rats treated with the same regimens as in Figure 2B 
(***, P < .0001 using the Mann-Whitney test). D, Correlation between the decrease in vegetation bacterial loads and the vegetation phage titers resulting from in situ phage 
amplification (continuous infusion and bolus injection pooled together; correlation value [r] = −0.66; Pearson 2-tailed correlation test: P = .003). Abbreviation: cip, ciprofloxacin.
6 • JID 2017:XX (XX XXXX) • Oechslin et al
verify this hypothesis. Figure 6A shows that these resistant iso-
lates had markedly different phage susceptibility profiles when 
compared with the parent strain. Mutant 24/2 conferred tur-
bid plaques, whereas mutant 19/2 was resistant to 10 of the 12 
phages and displayed a melanized (dark colonies) phenotype.
To determine whether these mutants had altered virulence, 
they were tested for their capability to infect sterile vegetations. 
A  single bolus of 108 CFUs (ie, infective dose 90% of parent 
strain) led to the infection of <60% (P < .05) and <30% (P < .01) of 
vegetations for mutants 19/2 and 24/2, respectively (Figure 6B). 
Moreover, the median bacterial densities in the infected vege-
tations were significantly lower than in rats infected with the 
parent strain (CHA: 8.9 CFUs/g; 24/2: 7.3 CFUs/g; and 19/2: 6.8 
CFUs/g; P < .05), and blood cultures were negative.
To further investigate the origin of this impaired in vivo infec-
tivity, the genomic DNA of the parent strain CHA and the 2 
mutants was sequenced, assembled, and compared (Figure 7A). 
Mutant 24/2 displayed a 15-basepair deletion at the 3’ end of the 
pilT gene (Supplementary Figure 4), which encodes an ATPase 
involved in motility [25]. As a result, mutant 24/2 exhibited loss 
Figure 4. Light microscopy and transmission electron microscopy of rat vegetations after 6 hours of phage therapy. A, Semithin section (200 nm) of control vegetation infected 
with Pseudomonas aeruginosa CHA stained using the modified Braun Brenn staining protocol [37]. Arrows indicate bacteria, stained in red. B, Transmission electron microscopy 
of ultrathin sections (50 nm) of control vegetation infected with P. aeruginosa CHA positive-stained using uranium acetate and lead citrate. Arrows indicate bacteria. C, Example 
of a negative staining of a myoviridae phage present in the cocktail; other phages morphotypes including podoviridae were also present. D, Transmission electron microscopy of 
vegetation infected by P. aeruginosa CHA and treated with the phage cocktail. Arrows indicate phage capsids inside lysed bacteria. Abbreviation: RBC, red blood cell.
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of twitching motility (Figure  7B). Mutant 19/2 had a 362-kb 
genomic deletion encompassing 342 genes. These included the 
galU gene, which is involved in P. aeruginosa LPS core synthe-
sis. galU deletion was shown to be responsible for phage resis-
tance [26]. The resulting absence of O antigen and LPS core 
truncation was confirmed by LPS extraction followed by gel 
electrophoresis (Figure 7C). Mutant 19/2 also showed a 3-fold 
decrease in its MIC of ciprofloxacin (0.064 vs 0.192 µg/mL for 
mutant 19/2 and parent CHA, respectively).
DISCUSSION
Although phage therapy is a promising alternative to antibi-
otics against specific and difficult-to-treat infections, careful 
appraisal of its therapeutic potential is an absolute prerequisite 
before clinical application.
Here we evaluated the in vitro activity of the whole phage 
cocktail and its individual phage components against a panel 
of independent P. aeruginosa isolates in test tubes and in fibrin 
clots. This revealed the presence of bacterial strains with oppo-
site susceptibility profiles, either resistant to all of the cocktail’s 
phages (eg, strain PA7) or susceptible to all of them (eg, strain 
CHA). The frequency of spontaneous phage resistance muta-
tions of the susceptible strain CHA was found to be ca 10–7. This 
predicted that phage resistance would emerge in infected fibrin 
clots, which contained ≥108 CFUs/g. This was indeed the case. 
However, these approach experiments highlighted 2 additional 
important facts. First, phages could readily diffuse into clots, 
kill the overwhelming majority of phage-susceptible bacteria in 
situ, and protect the fibrin matrix from bacterial-induced disin-
tegration. Second, combining phages with low concentrations 
of ciprofloxacin or meropenem (2.5 × the MIC) inhibited the 
regrowth of phage-resistant mutants, suggesting potential suc-
cess of in vivo therapy.
The in vivo experiments provided further critical informa-
tion. Regarding PK/PD parameters, phages were relatively 
stable in plasma (elimination half-life of ca 2.3 hours follow-
ing bolus administration) and persisted longer in organs (half-
life up to 9 hours). These values were consistent with those 
observed in previous work [27] and confirmed that phages, 
whose sizes vary from ca 50  nm to 200  nm, can diffuse into 
various body compartments [5, 6, 28]. As a result, phages were 
able to kill bacteria inside valve vegetations and multiply locally 
by up to 3 log PFUs/g within 6 hours. Phage-induced killing 
correlated with a burst of IL-1β and IL-6. Because cytokine lev-
els were measured only at a single time point, the data did not 
permit extrapolating the dynamics of cytokine responses over 
time. However, the significant increase in IL-1β and IL-6 levels 
in rats treated with phages—as compared with rats treated with 
ciprofloxacin—most likely reflected the release of cell debris by 
phage-mediated lysis. Accordingly, it is known that both cyto-
kines are inducible by LPS [29] and that similar results were 
obtained in EE using a bactericidal phage lysin [30].
Figure 5. Cytokine quantification in rat plasma during experimental endocarditis. 
A, Protocol of blood sampling for cytokine quantification. B, Levels of interleukin 1β 
(IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) measured after 6 
hours of phage or antibiotherapy (treatment). Controls included rats 24 hours after 
surgery (inoculum, T0), untreated but infected rats for 18 hours or 24 hours (bacteria 
T18 and T24), and uninfected rats receiving phage for 6 hours (Phages T6). Each 
value represents the mean  ±  SEM from 4–10 individual animals (*, P  =  .03; **, 
P = .005 using the Mann-Whitney test). Abbreviation: cip, ciprofloxacin.
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From a therapeutic point of view, the combination of phages 
with ciprofloxacin exhibited a highly synergistic effect and 
resulted in 7 of 11 (64%) negative valve cultures within 6 hours. 
This remarkable result has no precedent in antimicrobial ther-
apy of EE with virtually any drug or pathogen, especially not 
with P. aeruginosa [31–33].
Phage-antibiotic (or PAS) synergism has been formerly 
reported [34–37]. The mechanism of PAS is proposed to 
result from antibiotic-induced bacterial elongation, which 
may facilitate the access of phages to their bacterial target 
[37]. However, none of the previous PAS studies were done 
in vivo, and none of them demonstrated the extensive kill-
ing of >7 orders of magnitude in 6 hours reported herein 
[34–37]. Interestingly, phage-resistant subpopulations were 
readily detected in broth cultures and infected clots, but not 
in vegetations. This suggests that preexisting phage-resistant 
mutants might be hampered in vivo, as proposed by others [6, 
11, 12, 38, 39].
In fact, the mutations that conferred resistance to the phage 
cocktail came at a great physiological cost. The present experi-
ments provide 2 examples supporting this notion. Mutant 24/2 
exhibited defective cell motility due to disruption of the pilT 
gene, whose product is an ATPase providing energy for type IV 
pilus contraction and bacterial twitching [25]. Type IV pilus is 
also a phage receptor, and pilus contraction is believed to bring 
the phages closer to the bacterial envelope [40]. Mutant 19/2 
had a truncated LPS resulting from a large deletion encom-
passing the galU gene involved in the synthesis of the LPS core 
[26, 41]. LPS can also act as a phage receptor, and its alteration 
can confer phage resistance [13]. Both type IV pili and LPS are 
major virulence factors in P. aeruginosa, and their mutation can 
result in attenuated virulence [13, 42]. Thus, while these muta-
tions confer resistance to phages, they may also decrease fitness 
in animals while preserving normal growth in less stringent in 
vitro conditions.
Although these observations are promising regarding 
phage antibacterial activity, caution should be raised as to 
the use of phage cocktails versus single-phage preparations. 
Although phage cocktails provide broader strain coverage 
than single phages, they also carry greater risks of unwanted 
gene transfer and interphage interference. Ideally phages 
should be tailored against their target pathogen, and speci-
ficity should be preferred to exhaustiveness, just like for anti-
biotic therapy.
Altogether our results provide a strong proof of concept for 
phage therapy of deep-seated and systemic infections. Moreover 
they raise the provocative possibility that certain infections 
might be cured by a single phage injection most efficiently 
Figure 6. Infectivity of phage-resistant Pseudomonas aeruginosa mutants in rats with catheter-induced vegetations. A, Two phage resistant P. aeruginosa mutants, 24/2 
and 19/2, were isolated in vitro from fibrin clots and showed different phage resistance patterns. Lysis zones at the site of the phage deposits indicated phage-sensitivity. 
The absence of lysis indicated phage resistance. B, The isolates’ infectivity was tested in rats with catheter-induced vegetations. Both variants showed a loss of infectivity 
(>40% for 24/2 and >70% for 19/2) as compared with the parent strain CHA. P values were determined using Fisher’s exact test.
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combined with synergistic antibiotics. Indeed, once locally 
established, phages can multiply in situ and do not necessitate 
further administration.
Supplementary Data
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online. Consisting of data provided by the authors to benefit the reader, the 
posted materials are not copyedited and are the sole responsibility of the 
authors, so questions or comments should be addressed to the correspond-
ing author.
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